All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-01-20T15:03:35.000Z

Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?

By Alia Mohamed
Featured
Aaron Gerds
Jan 20, 2020
Share:

Bookmark this article

The MPN Hub were pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. We asked: Could pacritinib represent a new efficacious treatment for patients with myelofibrosis who have failed ruxolitinib?

Aaron Gerds discusses the PAC203 study that evaluated the efficacy of the JAK inhibitor, pacritinib, in patients with myelofibrosis and low platelet counts, he talks about the patient characteristics, the optimal dose, safety, response rates and overall outcomes of patients. He also discusses the place of pacritinib in the treatment pathway and its effect on patient outcomes.

Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?

More about...
ASH 2019FedratinibJAK2 driver mutationsMPN driver mutationsMyeloproliferative neoplasmsPAC203PacritinibPrimary myelofibrosisRuxolitinib

Related articles

Add bookmark

Reviewing the safety of JAK inhibitors for the treatment of myelofibrosis

Over the past decade, seminal studies have led to the identification of specific driver mutations in the pathogenesis of myelofibrosis (MF) and related myeloproliferative...

Mar 20, 2021
Add bookmark

Reviewing the safety of JAK inhibitors for the treatment of myelofibrosis

Over the past decade, seminal studies have led to the identification of specific driver mutations in the pathogenesis of...

Mar 20, 2021
Add bookmark

Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms

The bone marrow niche is the local tissue microenvironment that maintains and regulates stem cells for hematopoiesis. It is comprised of many...

Sep 21, 2020
Add bookmark

Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms

The bone marrow niche is the local tissue microenvironment that maintains and regulates stem...

Sep 21, 2020

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox